Results 101 to 110 of about 77,790 (265)
Abstract Discourse around drug policy presents a stark contrast between policing and harm reduction models, sparking debates on the state's regulatory versus protective role. Canada is an ideal case to study drug policy models due to its global recognition as a leader in harm reduction alongside continued reliance on policing of drugs.
Taylor Domingos
wiley +1 more source
Exploring the Materiality of Data Breach Disclosures on the Australian Stock Exchange
This study examines Australian Stock Exchange (ASX) data breach announcements to provide insights into the extent and nature of data breach disclosures, as well as the costs, particularly to stakeholder relationships. Using a dataset of all data breach‐related announcements on the ASX, we identify a lack of data breach disclosure and, where disclosures
Jane Andrew +3 more
wiley +1 more source
Comparative Clinical Trajectories Across Cannabis‐Related and Nonsubstance‐Related Psychoses
ABSTRACT Background Research indicates that first‐episode psychosis (FEP) with cannabis use disorder (CUD) carries a substantial disease burden, but more granular clinical trajectories of cannabis‐related psychoses remain unclear. This study examines the clinical trajectories of first clinically diagnosed FEP&CUD and cannabis‐induced psychosis (CIP) in
Antti Mustonen +7 more
wiley +1 more source
Electroconvulsive Therapy and Time to Psychiatric Readmission in Schizophrenia
ABSTRACT Introduction There is evidence that electroconvulsive therapy (ECT) can augment the effects of antipsychotics in schizophrenia. However, there is limited evidence from Western populations on whether ECT reduces the risk of relapse compared to non‐ECT treatment in schizophrenia.
Linnea Stenmark +2 more
wiley +1 more source
Abstract Background and aims Patterns of daily or near‐daily (DND) use of alcohol and cannabis among adults in the United States have been changing. The current study measured how these shifts have occurred across developmental periods of adulthood. Design, Setting, and Participants U.S.
Megan E. Patrick
wiley +1 more source
UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Epilepsy
Background A third of epilepsy patients fail to enter seizure remission despite optimal therapeutic management. Cannabis‐based medicinal products (CBMPs) have shown promise as a potential therapy.
Isaac Cowley +11 more
doaj +1 more source
UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia
Introduction The primary aim of this study was to assess changes in sleep‐specific health‐related quality of life (HRQoL) for those prescribed cannabis‐based medicinal products (CBMPs) for insomnia.
Kavyesh Vivek +7 more
doaj +1 more source
Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper +7 more
wiley +1 more source
Cannabis (Cannabis sativa L) is a versatile crop from which highly nutritious seed extracts and several pharmaceutical grade flower cannabinoids can be isolated and purified.
Emmanuel Wilson Mhuru +7 more
doaj +1 more source

